Table 3.
Clinical follow-up and outcome judgement in patient with psoriasis still taking biological agents
| Outcomes | Adalimumab 9 (9.9) |
Etanercept 22 (62.9) |
Infliximab 60 (54.0) |
Total 91(100) |
|---|---|---|---|---|
| Annual review | ||||
| A—consults* | 9 (100) | 22 (100) | 60 (100) | 91 (100) |
| B—laboratorial examinations† | 7 (77.8) | 15 (68.2) | 46 (76.7) | 68 (74.8) |
| Clinical monitoring adequate | ||||
| C—A+B | 7 (77.8) | 15 (68.9) | 46 (76.4) | 68 (74.8) |
| Therapies | ||||
| None | 0 (0.0) | 3 (13.6) | 14 (23.3) | 17 (18.7) |
| Only topical | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Only phototherapy | 0 (0.0) | 1 (4.5) | 4 (6.7) | 5 (5.5) |
| Only N-BIOSYS‡ | 7 (77.8) | 9 (40.9) | 18 (30.0) | 34 (37.4) |
| Combination of therapies prior to the use of biologics, n (%) | ||||
| Topical +phototherapy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| D—topical+N-BIOSYS‡ | 1 (11.1) | 3 (13.6) | 8 (13.3) | 12 (13.2) |
| Phototherapy+N-BIOSYS‡ | 1 (11.1) | 4 (18.2) | 13 (21.7) | 18 (19.8) |
| E—topical+phototherapy+N-BIOSYS | 0 (0.0) | 2 (9.1) | 3 (5.0) | 5 (5.5) |
| F—recommended use of biological agents according to guidelines | ||||
| D+E | 1 (11.1) | 5 (22.7) | 11 (18.3) | 17 (19.3) |
| Adherence of guideline | ||||
| Prior drugs and monitoring (C+D) | 1 (11.1) | 3 (13.6) | 9 (15.0) | 13 (14.2) |
*At least one annual medical consult; blood differential (complete blood cell count), liver function tests.
†Blood differential (complete blood cell count), liver function tests.
‡Use of biological agent after treatment with topic and one systemic non-biological agent.